The mechanisms by which prostate cancer metastasizes to bone with a strong osteoblastic reaction remain poorly understood. Several factors have been previously implicated, including transforming growth factor-b, ®broblast growth factors, endothelin-1 and bone morphogenetic proteins (BMPs). BMP-6 expression has been shown exclusively in the malignant epithelial cells of prostate cancers that have metastasized, but not in organ con®ned disease. Expression of BMP-6 in radical prostatectomy specimens has been shown to correlate with increased recurrence rates and decreased survival. This article presents the results of work by the authors' group in this ®eld and a current literature review.
Introduction
The most common cause of morbidity in advanced prostate cancer is skeletal metastasis with a predilection for the axial skeleton. These metastases contain areas of osteolysis and osteoscierosis but the sclerotic areas predominate, with increased osteoblastic activity. This is in stark contrast to the majority of bony secondaries from other malignancies, which are osteolytic in nature, with increased bone resorption and osteoclastic activity.
The mechanisms behind the metastatic process in prostate cancer remain poorly understood. Previous studies have demonstrated that benign and malignant prostate cells express a number of growth factors, including transforming growth factor-b (TGF-b), plasminogen activator, ®broblast growth factors (FGFs) and epidermal growth factor (EGE). 1,2 However, to date, none of these factors has been speci®cally implicated with this process.
Current thinking suggests that some factors, produced by the tumour cells, such as TGF-b, FGFs, bone morphogenetic proteins (BMPs) and endothelin-l (ET-l) may directly stimulate osteoblastic cells and subsequent bone formation. Other factors released by the tumour cell may act indirectly. Proteases such as prostate speci®c antigen (PSA), human kalikrein 2 and urokinase plasminogen activator (uPA) activate latent TGF-b and release insulin-like growth factor (IGF) from its inhibitory binding protein, allowing these factors to act on the osteoclast. These proteases also inactivate parathyroid related protein (PTHrP), which is known to be a mediator of osteolysis. 3 The prostate cancer cells must undergo a series of phenotypic changes to enable them to metastasize and then grow within the skeleton. There are clear associations between prostate cancer cells and the various cells involved in the transition from osteoprogenitor cell to mature osteoblast. The LNCaP cell line has been shown to express several of the extracellular matrix proteins which are expressed by maturing osteoblasts, and the expression increased with increasing tumourigenicity and metastatic potential of the cell line.
Similarly, many of the growth factors mentioned above are known to be important in the growth factor cascade of the osteoblast, indicating that there may well be a reciprocal interaction between metastatic prostate cancer cells and bone stromal cells. These events have recently been proposed as a step-wise hypothesis, elegantly described by Koenemann et al. 4 The ®rst or`early' phase of bone metastasis is growth of the prostate cancer cells within the skeleton, which is driven by bFGF and IGEs. During this stage, the release of PSA by the cancer cells is suppressed by high levels of TGF-b These three growth factors are highly abundant in the bone matrix and their action may well be potentiated by ET-l and uPA.
Once the cancer cells have established growth, they begin to secrete PSA, PTHrP and thrombospondin-l, which is a matrix protein. The PSA inactivates PTHrP, and increases the levels of IGF as described above. The thrombospondin-l, together with PSA, uPA and hK2, activate TGF-b which in turn activates BMPs, leading to deposition and remodelling of bone matrix proteins.
In the third, or advanced, stage the low or absent levels of PTHrP, combined with high levels of BMPs, bFGF, EGF, keratinocyte growth factor (KGF) and ET-l cause an osteoblastic reaction. The osteoblastic cells become terminally differentiated, deposit bone matrix proteins, and upregulate alkaline phosphatase induction and uptake of calcium, which leads to the formation of woven bone.
Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs) were originally de®ned by Urist in 1965 as an activity derived from bone that induces ectopic bone formation in vivo. 5 Thus far 15 BMPs have been identi®ed and they are all members of the TGF-b superfamily, with the exception of BMP-1. 6 Their osteoinductive ability in vivo has stimulated potential therapeutic applications in reconstructive orthopaedic, periodontal and craniofacial surgery. However relatively little work has been done to link BMP activity with prostate cancer.
Previous work
The authors' group has reported previously the association between BMPs and skeletal metastases in prostate cancer, in a number of studies. The ®rst of these studies investigated the expression of BMPs-1±6 in benign and malignant prostate tissues. Using the polymerase chain reaction, prostatic tissue of patients with benign prostatic hyperplasia, non-metastatic prostatic adenocarcinoma and metastatic prostatic adenocarcinoma was screened. All the BMPs were expressed in the different tissues to varying degrees. However, BMP-6 was expressed only in patients with prostatic adenocarcinoma. When the nonmetastatic and metastatic groups were compared, expression of each of the BMPs was increased in the metastatic group. Most signi®cantly, BMP-6 was the only protein that was not expressed in the non-metastatic group but was in 55% of patients with established skeletal metastases. 7 BMP-6 mRNA and protein expression was subsequently investigated in malignant and benign prostatic tissue using in situ hybridization and immunohistochemistry. 8 This study showed that mRNA for BMP-6 was exclusively detected in the cytoplasm of malignant prostatic epithelial cells, with no signals in the prostatic stroma. None of the BPH samples or benign prostatic tissue present in sections containing prostate cancer showed any evidence of BMP-6 gene expression.
In those patients with proven skeletal metastases, 95% showed cytoplasmic signals for BMP-6 mRNA compared with only 18% of those with apparently localized cancer (P`0.0001). Using immunohistochemistry, all primary tumours with established metastatic disease showed positive cytoplasmic staining for BMP-6 in malignant prostatic epithelial cells, compared to four out of 11 tumours with apparently localized cancer (P`0.0001). BMP-6 protein was also detected in basal cell layers and areas of basal cell hyperplasia in both benign and malignant tissue.
In a further study, BMP-6 expression was analysed in skeletal metastases from prostate cancer and compared with skeletal metastases from other malignancies, by in situ hybridization. 9 Primary tumours included prostate (n 13), lung (n 8), kidney (n 2), breast (n 5), colon (n 1) and uterus (n 1). In addition primary tumour was obtained for three of the patients with prostate secondaries from transurethral resection specimens. In skeletal metastases from prostate cancer, BMP-6 mRNA expression was observed in 11 out of 13 (89%) patients compared with ®ve out of 17 (29%) from non-prostatic malignancies. Signals were observed in the skeletal deposits from breast, colon and lung, but the signals were much weaker than those from the prostatic deposits. Expression of BMP-6 was absent in the deposits from renal and uterine carcinomas. In the three paired prostatic primaries and secondaries, there was expression in both lesions which was exclusive to malignant epithelial cells.
More recently, a retrospective analysis of patients undergoing radical prostatectomy was undertaken to investigate the potential prognostic value of BMP-6 expression in clinically organ-con®ned disease. Eightyone specimens were studied from three European centres. The follow-up period had a range of 5±160 months, with a median of 47 months. BMP-6 expression was found in the malignant epithelial cells in 64 (79%) of the patients and its expression did not appear to correlate with tumour grade or pathological stage. Over the follow-up period 31 of the 64 (49%) patients with BMP-6 positive tumours showed evidence of biochemical progression, and 23 of the 64 (34%) showed evidence of clinical progression. None of the BMP-6 negative tumours showed evidence of biochemical or clinical progression. 10 So far this work has only shown an association between BMPs and skeletal metastases in prostate cancer. Albeit compelling, this association does not provide evidence to suggest that BMPs are either directly responsible for the formation of metastases, or cause the osteoblastic reaction seen at the secondary sites. BMPs are known not to act alone, and are part of a complex cascade of events leading to their inhibition or activation. They are only players, of uncertain importance, in a bigger picture controlling the activation of osteoblasts in the context of the prostate cancer cell/bone stroma interaction.
The precise action of the bone morphogenetic proteins, especially BMP-6, in the formation of skeletal metastases in prostate cancer requires further investigation. This necessitates the use of in vitro and in vivo studies and this work is ongoing within our group.
